The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.
Study Type
OBSERVATIONAL
Enrollment
13
Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
Productos Roche S.A. Quimica e Industrial, División Farmacéutica
Buenos Aires, Argentina
Percentage of Participants with Adverse Events (AE)
Time frame: Up to approximately 2 years.
Percentage of participants with Confirmed Objective Response (ORR) of Complete Response (CR) or Partial Response (PR)
Time frame: Up to approximately 2 years.
Duration of Response (DOR)
Time frame: Up to approximately 2 years.
Progression Free Survival (PFS)
Time frame: Up to approximately 2 years.
Overall Survival (OS)
Time frame: Up to approximately 2 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.